Mentions
Extended reach
Total likes
Video views
AI synopsis
The collective discussions cite official approvals, expert panels, and recent publications, highlighting the significance and clinical relevance of biosimilars. The tone emphasizes their value with words like 'reviewed,' 'new report,' and 'approved,' which convey seriousness and importance, although some posts remain informational rather than deeply analytical.
Most discussions support the idea that biosimilars are beneficial and important in oncology, aligning with their recognition as effective and cost-saving options.
The posts show high interest, referencing new reports, approvals, and expert reviews, indicating active engagement with recent developments.
Posts reference multiple sources, expert opinions, and recent literature, showing a moderate level of deeper engagement.
The discussions reflect recognition of biosimilars' potential to influence cost savings and treatment options, suggesting a moderate impact on healthcare practices.
Our latest @ASCO update on #Oncology Biosimilars is now published @JCOOP_ASCO @gary_lyman @rschilsky @DrScottTagawa @Cancer_CCFla https://t.co/3LKsUVE2a1
Now available: New report on the use of #biosimilar medications in oncology ➡️ https://t.co/BQ73087K0q https://t.co/jmJrV29O4P
An Expert Panel reviewed medical literature and provided summary of currently approved biosimilar therapeutics for cancer treatment or supportive care in the US. Use of Biosimilar Medications in Oncology https://t.co/1rAkH4GKeX
#JCOOP @drznahleh: This @ASCO Special Article focuses on the use of #biosimilars in oncology, including definitions, approvals, use, interchangeability, value & post-approval monitoring. https://t.co/5NFnTuU7x8 #medonc https://t.co/ZYa13SNpFB
Use of Biosimilar Medications in Oncology https://t.co/tdDVxzFJsu
Una revisión general del uso de #biosimilares en oncología. De interés para una primera aproximación a lo que está ocurriendo en EEUU. https://t.co/rSFdXnVPEV
This video discusses the growing use of biosimilar medications in cancer treatment, highlighting approved biosimilars in the US and emphasizing their effectiveness and potential cost savings.
Use of Biosimilar Medications in Oncology https://t.co/tdDVxzFJsu
FDA has approved 17 cancer medications (biosimilars for bevacizumab, trastuzumab, and rituximab) or supportive care agents for cancer care (biosimilars for filgrastim, peg-filgrastim, and epoetin alpha). #biosimilar @ASCO @JCO_ASCO @FDAOncology https://t.co/W4AhddtxEh
Advances in cancer care have been accompanied by rising health care costs. Strategies to lower the overall cost of expensive oncology pharmaceuticals and cost-containment approaches have lead to the development of biosimilars. - https://t.co/ZGmc3McNLT
ASCO Special Article: Use of Biosimilar Medications in Oncology https://t.co/5zRPDvi5I0
RT @irodriguezpenin: Use of Biosimilar Medications in Oncology https://t.co/nE8XOK8juR
RT @irodriguezpenin: Use of Biosimilar Medications in Oncology https://t.co/nE8XOK8juR
Use of Biosimilar Medications in Oncology https://t.co/nE8XOK8juR
RT @xXNeCXx: 1/ Use of Biosimilar Medications in Oncology, 22 Jan 2022 #DDDD $LBPS Source: https://t.co/eVPskOpjQV #fintwit #investing #m…
RT @xXNeCXx: 1/ Use of Biosimilar Medications in Oncology, 22 Jan 2022 #DDDD $LBPS Source: https://t.co/eVPskOpjQV #fintwit #investing #m…
1/ Use of Biosimilar Medications in Oncology, 22 Jan 2022 #DDDD $LBPS Source: https://t.co/eVPskOpjQV #fintwit #investing #microbiome #multibagger #stocks #StockMarket https://t.co/pk2VcQi6TN
#JCOOP @drznahleh: This @ASCO Special Article focuses on the use of #biosimilars in oncology, including definitions, approvals, use, interchangeability, value & post-approval monitoring. https://t.co/5NFnTuU7x8 #medonc https://t.co/ZYa13SNpFB
RT @drznahleh: Our latest @ASCO update on #Oncology Biosimilars is now published @JCOOP_ASCO @gary_lyman @rschilsky @DrScottTagaw…
RT @drznahleh: Our latest @ASCO update on #Oncology Biosimilars is now published @JCOOP_ASCO @gary_lyman @rschilsky @DrScottTagaw…
RT @drznahleh: Our latest @ASCO update on #Oncology Biosimilars is now published @JCOOP_ASCO @gary_lyman @rschilsky @DrScottTagaw…
RT @drznahleh: Our latest @ASCO update on #Oncology Biosimilars is now published @JCOOP_ASCO @gary_lyman @rschilsky @DrScottTagaw…
Our latest @ASCO update on #Oncology Biosimilars is now published @JCOOP_ASCO @gary_lyman @rschilsky @DrScottTagawa @Cancer_CCFla https://t.co/3LKsUVE2a1
RT @VriesElisabeth: An Expert Panel reviewed medical literature and provided summary of currently approved biosimilar therapeutics for canc…
RT @ASCO: Now available: New report on the use of #biosimilar medications in oncology ➡️ https://t.co/BQ73087K0q https://t.co/jmJrV29O4P
An Expert Panel reviewed medical literature and provided summary of currently approved biosimilar therapeutics for cancer treatment or supportive care in the US. Use of Biosimilar Medications in Oncology https://t.co/1rAkH4GKeX
RT @ASCO: Now available: New report on the use of #biosimilar medications in oncology ➡️ https://t.co/BQ73087K0q https://t.co/jmJrV29O4P
RT @ASCO: Now available: New report on the use of #biosimilar medications in oncology ➡️ https://t.co/BQ73087K0q https://t.co/jmJrV29O4P
Now available: New report on the use of #biosimilar medications in oncology ➡️ https://t.co/BQ73087K0q https://t.co/jmJrV29O4P
Use of Biosimilar Medications in Oncology https://t.co/cQKcbRZ5I3 https://t.co/kP8Xdly1oj
Una revisión general del uso de #biosimilares en oncología. De interés para una primera aproximación a lo que está ocurriendo en EEUU. https://t.co/rSFdXnVPEV
Use of Biosimilar Medications in Oncology now available in JCO Oncology Practice (https://t.co/Zi0wwT4C5o) https://t.co/fY6E7ibQTo